GO
| HSI1 | 24,642.51 | +132.42 | 177.48B |
| HSCEI1 | 8,216.84 | +51.06 | 51.28B |
| Back Zoom + Zoom - Block Traded | |
|
HUTCHMED Initiates Clinical Trial of KRAS-EGFR Antibody-Targeted Conjugate Therapy HMPL-A830
2026-09-28 08:54:19 HUTCHMED (00013.HK) announced it has initiated the Phase Ia part of a global clinical trial of HMPL-A830 in patients with unresectable, advanced or metastatic solid tumors. The first patient received the first dose in China on September 24, 2026. An Antibody-Targeted Therapy Conjugate (ATTC) enables tumor-specific activity of potent, cell-killing, targeted therapy payloads by leveraging antibody-guided delivery. This first-in-class ATTC drug candidate comprises a highly selective and potent Kirsten rat sarcoma (KRAS) small molecule inhibitor payload conjugated to an anti-epidermal growth factor receptor (EGFR) antibody. Colorectal, pancreatic and lung cancers have the highest incidence of patients with KRASaltered tumors, who often lack a safe and durable KRAS therapy. HMPL-A830 is designed to address this need by delivering a KRAS inhibitor directly to EGFR-expressing tumors, while simultaneously blocking EGFR and KRAS signaling to enhance efficacy, durability, and tolerability. ~ AASTOCKS Financial News Website: www.aastocks.com | |